title: Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.
abstract: Dimethyl fumarate (DMF), a fumaric acid ester, is a new orally available disease-modifying agent that was recently approved by the US FDA and the EMA for the management of relapsing forms of multiple sclerosis (MS). Fumaric acid has been used for the management of psoriasis, for more than 50 years. Because of the known anti-inflammatory properties of fumaric acid ester, DMF was brought into clinical development in MS. More recently, neuroprotective and myelin-protective mechanism actions have been proposed, making it a possible candidate for MS treatment. Two Phase III clinical trials (DEFINE, CONFIRM) have evaluated the safety and efficacy of DMF in patients with relapsing-remitting MS. Being an orally available agent with a favorable safety profile, it has become one of the most commonly prescribed disease-modifying agents in the USA and Europe.
authors: UT Southwestern, Dallas, TX, USA.
authors: Duvyanshu
authors: D
authors: Dubey
authors: Bernd C
authors: BC
authors: Kieseier
authors: Hans P
authors: HP
authors: Hartung
authors: Bernhard
authors: B
authors: Hemmer
authors: Clemens
authors: C
authors: Warnke
authors: Til
authors: T
authors: Menge
authors: William A
authors: WA
authors: Miller-Little
authors: Olaf
authors: O
authors: Stuve
mesh_terms: D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D000069462:Dimethyl Fumarate / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D000069462:Dimethyl Fumarate
keywords: dimethyl fumarate; experimental autoimmune encephalomyelitis; immunology; multiple sclerosis; pharmacology